Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Last year, The experimental drug KarXT, developed by Karuna Therapeutics, is expected to receive FDA approval later this month (Sept. 26), marking a significant breakthrough in schizophrenia treatment.
由karuna therapeutics开发的实验药物KarXt预计将于本月后期（9月26日）获得FDA批准，这标志着精神分裂症治疗方面的重要突破。
If approved, KarXT would become the first novel schizophrenia drug in over 70 years, offering new hope for patients and medical professionals alike.
如果获得批准，KarXt将成为70年来首个新型精神分裂症药物，为患者和医务人员带来新的希望。
Schizophrenia, a mental disorder that affects approximately 3.8 million adults in the U.S., is often characterized by severe symptoms such as social isolation, memory issues and psychotic episodes.
精神分裂症是一种影响美国约380万成年人的精神障碍，常以社交隔离、记忆问题和幻觉发作等严重症状为特征。
Last year, Bristol-Myers Squibb & Co (NYSE:BMY) acquired Karuna Therapeutics for $330 per share in cash for a total equity value of $14 billion, or $12.7 billion net of estimated cash acquired.
去年，百时美施贵宝（纽交所：BMY）以每股330美元的现金收购了Karuna Therapeutics，总权益价值为140亿美元，或考虑到预计现金收购后净额为127亿美元。
The Financial Times highlights that existing treatments, mainly focused on blocking dopamine receptors, often come with serious side effects, including weight gain and involuntary movements.
《金融时报》指出，现有的治疗方案主要集中在阻断多巴胺受体上，往往伴随严重副作用，包括体重增加和不自主运动。
Despite the enthusiasm surrounding KarXT, the complexity and financial constraints of the U.S. health care system could limit access to this new treatment.
尽管围绕KarXt存在着热情，但美国医疗保健系统的复杂性和财政限制可能限制对这种新治疗的获取。
High drug pricing could also hinder access; the Institute for Clinical and Economic Review has suggested KarXT be priced at up to $20,000 per year.
高昂的药品定价也可能阻碍获取；临床与经济评估研究所建议，KarXt的定价可达每年最多2万美元。
In August, AbbVie Inc (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics, another company focused on developing drugs for neurological disorders, for a total equity value of approximately $8.7 billion, or $45 per share in cash.
今年8月，艾伯维公司（纽交所：ABBV）完成了对Cerevel Therapeutics的收购，后者是另一家专注于研发神经疾病药物的公司，总权益价值约为87亿美元，或每股现金45美元。
The challenges extend beyond the cost and availability of medications, the Financial Times report adds. Many individuals with mental health conditions, particularly schizophrenia, encounter law enforcement rather than health care professionals during crises.
挑战不仅仅在于药物的成本和可获性，据《金融时报》报道。许多患有精神疾病，特别是精神分裂症的个人，在危机期间遇到执法人员，而非医护人员。
While KarXT's approval could represent a crucial step forward, many experts, including Michael Thompson, a criminal justice expert, say that more systemic changes are needed to ensure mental health care is accessible and effective, especially for vulnerable populations like the homeless, according to FT.
尽管KarXT的批准可能代表着一个重要的进步，但许多专家，包括刑事司法专家迈克尔·汤普森（Michael Thompson）表示，为了确保精神康复治疗的可及性和有效性，特别是对于像无家可归者这样的弱势人群，更需要进行系统性的改变。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
- Zevra Therapeutics的药物成为首个获得FDA批准用于超稀有神经退行性疾病的治疗
Photo via Pixabay.
图片来自Pixabay。
